We have previously shown that extracts of different Epilobium species, a phytotherapeutic agent used in folk medicine as a treatment for benign prostatic hyperplasia, inhibit proliferation of human prostate cells. The selectivity of this effect was evaluated in four different human cell lines (PZ-HPV-7, normal prostate cells; LNCaP, transformed prostate cells; HMEC, mammary cells, and 1321N1, astrocytoma cells). Different extracts of Epilobium species (E. rosmarinifolium, E. spicatum, and E. tetragonum) had similar growth-inhibitory effects in all cell lines tested, indicating a lack of specificity for prostate cells. Inhibition of DNA synthesis was mostly due to the nonpolar fraction of the extracts which is expected to contain flavonoids and sterols. Polar fractions were devoid of activity with the exception of that from E. rosmarinifolium. This species is the most potent in the antiproliferative effect and contains the highest concentration of oenothein B, a hydrolyzable ellagitannin. Oenothein B inhibited DNA synthesis in all four cell lines tested. Extracts of E. angustifolium (the Linné denomination of E. spicatum) and of E. spicatum from different sources were compared for their ability to inhibit DNA synthesis and for their oenothein B content. The E. angustifolium extract contained an amount of oenothein B 40-fold higher than the other extract of the same species and was ten times more potent in inhibiting DNA synthesis in a human prostate cell line. These results indicate that Epilobium extracts inhibit proliferation of prostate cells in a nonspecific manner. Oenothein B may play a role in this effect, but other active compounds are also present. The difference observed between extracts from the same species underscores the importance of determination and standardization of active ingredients in phytotherapeutic agents.
This study examined whether various species of Epilobium, a phytotherapeutic agent used in folk medicine as a treatment for benign prostatic hyperplasia, may have an antiproliferative effect in PZ-HPV-7 human prostatic epithelial cells in-vitro. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) test, [methyl-(3)H]thymidine incorporation into DNA and flow cytometry analysis were used to evaluate cell proliferation. Ethanolic extracts of E. spicatum, E. rosmarinifolium and E. tetragonum inhibited DNA synthesis in PZ-HPV-7 cells. While at high concentrations all extracts were cytotoxic, DNA synthesis was also decreased at levels that caused no or little cytotoxicity. Treatment of cells with Epilobium extracts did not result in a formation of DNA fragments (evaluated by the TUNEL assay) or chromatin condensation (assessed by Hoechst staining). Flow cytometry analysis indicated that Epilobium extracts inhibit the progression of the cell cycle from the G(0)/G(1) phase. These results suggest that extracts of Epilobium inhibit proliferation of human PZ-HPV-7 cells in-vitro by affecting progression of the cell cycle. This study provides some initial biological plausibility for the use of Epilobium extracts in benign prostatic hyperplasia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.